Xenpozyme is the first approved medication to treat symptoms that are not related to the central nervous system in patients with ASMD, a rare genetic disease that causes premature death.
Today, the agency amended the EUAs of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine to authorize bivalent formulations of the vaccines for use as a single booster dose at least two months following primary or booster vaccination.
Life expectancy fell in the United States in 2021 to its lowest since 1996, the second year of a historic retreat due to COVID-19 deaths, provisional government data showed on Wednesday.
Amgen announced Tuesday morning that its initial Phase III data of its oral drug Lumakras (sotorasib) met its primary endpoint of progression-free survival in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC).
The long-awaited review of problematic prescribing of opioids is taking longer than observers had hoped. Studies of this extended use of the pain medications have lagged for years beyond their expected completion, said FDA Commissioner Robert Califf to the Associated Press.
Omicron-adapted vaccines will be delivered to the European Union within days of regulatory approval, European member of parliament Peter Liese said on Wednesday.
The U.S. government expects its supply of COVID-19 vaccines and antiviral treatments to run out over the next year and is preparing for them to be sold via the commercial market, the Department of Health and Human Services said on Tuesday.
About one in four Americans live with some type of disability, according to the CDC, making disabled individuals the largest group of minorities in the country. However, their contributions are remarkedly underreported in the life sciences industry.
Texas on Tuesday reported the first death in a severely immunocompromised person who was diagnosed with monkeypox, according to state health department officials.
Pfizer signaled its interest in longevity research through a new partnership -and a $500,000 investment – in a decentralized drug development program driven by VitaDAO.
